Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
DAWN

DAWN - Day One Biopharmaceuticals, Inc. Stock Price, Fair Value and News

$11.77-0.56 (-4.54%)
Market Closed

22/100

DAWN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

22/100

DAWN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$9.56

Target 3M

$10.78

Target 6M

$10.16

DAWN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DAWN Price Action

Last 7 days

-2.5%

Last 30 days

25.6%

Last 90 days

67.2%

Trailing 12 Months

-10.9%

DAWN RSI Chart

DAWN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DAWN Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-7.96

Price/Sales (Trailing)

8.47

Price/Free Cashflow

-9.96

DAWN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$9.56

Target 3M

$10.78

Target 6M

$10.16

DAWN Fundamentals

DAWN Revenue

Revenue (TTM)

88.4M

Rev. Growth (Yr)

-57.56%

Rev. Growth (Qtr)

17.36%

DAWN Earnings

Earnings (TTM)

-151.8M

Earnings Growth (Yr)

-153.26%

Earnings Growth (Qtr)

34.94%

DAWN Profitability

Return on Equity

-33.66%

Return on Assets

-29.54%

Free Cashflow Yield

-10.04%

DAWN Investor Care

Shares Dilution (1Y)

1.81%

Diluted EPS (TTM)

-1.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
2024208.9M171.3M218.9M88.4M
2023153.9M165.5M177.2M188.9M
2022000142.2M
20210000
Get all data in R, Python etc through our Historical Stock Data APIs

About Day One Biopharmaceuticals, Inc.

DAWN
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
 CEO
 WEBSITEhttps://dayonebio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES124

Day One Biopharmaceuticals, Inc. Frequently Asked Questions

DAWN is the stock ticker symbol of Day One Biopharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Day One Biopharmaceuticals, Inc. is 1.21 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check DAWN's fair value in chart for subscribers.

The fair value guage provides a quick view whether DAWN is over valued or under valued. Whether Day One Biopharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Day One Biopharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DAWN.

As of Wed Jan 28 2026, DAWN's PE ratio (Price to Earnings) is -7.96 and Price to Sales (PS) ratio is 8.47. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DAWN PE ratio will change depending on the future growth rate expectations of investors.